Vita 34 AG: Chief Financial Officer of Vita 34 AG to seek new challenges
Chief Financial Officer of Vita 34 AG to seek new challenges
Falk Neukirch left Vita 34 AG on April 28, 2017, by mutual agreement and has resigned from his Management Board position
Leipzig, May 1, 2017 - On April 28, 2017, Falk Neukirch left Vita 34 AG as a Management Board member to take on new challenges. He resigned from the Management Board by mutual consent. Mr. Neukirch has run the Finance Department since 2015 and has played a significant role in the continually improved competitive position and growing profitability of Vita 34 AG, which has established itself as a reliable supplier and market leader for the storage of stem cells from umbilical cord blood in Europe in recent years.
As a member of the Management Board, Falk Neukirch was able to set decisive accents on the implementation of Vita 34 AG's growth strategy together with the Supervisory Board. In particular, the integration of acquired interests into one strong unit and the further advancement of international expansion into exciting growth markets are also due to his great commitment to the company.
The Chairman of the Supervisory Board of Vita 34 AG, Dr. Hans-Georg Giering, thanks Falk Neukirch for his commitment to the benefit of the company. "Falk Neukirch has decisively influenced the development of Vita 34 AG in a very important phase. In doing so, he played a key role in the development of important projects such as the sustained achievement of dividends and the Group's convergence into a strong entity." In particular, Dr. Giering emphasizes that he "regrets Falk Neukirch's personal decision to pursue new challenges. The entire Supervisory Board wishes Mr. Neukirch all the best for his future career development."
Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. More than 130,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.
01.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig
Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: email@example.com Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service